April - 2016

top of page

Sage Group News

Sage Represents Luzitin in Licensing of its Redaporfin Combination Therapy for Solid Tumours

Sage Represents Luzitin in Licensing of its Redaporfin Combination Therapy for Solid Tumours

Sage Represents Luzitin in Licensing of its Redaporfin Combination Therapy for Solid Tumours

Sage represents Luzitin (www.luzitin.pt) to develop a strategic alliance for its Redaporfin PDT combination therapy for solid tumours....

bottom of page